Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 4/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | THRA | P10827 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13589496 | 0.90 | CNR2 (0.41) | CNR2CNR1THRATHRBALDH1A1 | |
| SCHEMBL16066899 | 0.88 | CNR2 (0.39) | CNR2CNR1THRATHRBALDH1A1 | |
| SCHEMBL13618088 | 0.86 | CA9 (0.42) | CNR2CNR1ALDH1A1KDM4ETSHR | |
| SCHEMBL16066906 | 0.83 | CNR2 (0.42) | CNR2CNR1THRATHRBALDH1A1 | |
| SCHEMBL20285585 | 0.82 | HPGDS (0.44) | HPGDS | |
| SCHEMBL102846 | 0.81 | HPGDS (0.43) | HPGDSALDH1A1MEN1KMT2AMMP1 | |
| SCHEMBL99439 | 0.80 | HPGDS (0.44) | HPGDSALDH1A1KDM4ECYP2C9MMP1 | |
| SCHEMBL18601883 | 0.77 | ADRB2 (0.42) | KDM4ETSHRCYP2C9MEN1KMT2A | |
| SCHEMBL13697685 | 0.77 | ADRB2 (0.42) | KDM4ETSHRCYP2C9MEN1KMT2A | |
| SCHEMBL11912043 | 0.76 | HPGDS (0.40) | HPGDSALDH1A1KDM4ETSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641465-B1 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20090227547-A1 | Novel salt form of a Beta2-adrenergic agonist quinolin-2-one derivative | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-7582765-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7553971-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1446379-B1 | ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-7452995-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070225329-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227547-A1 | Novel salt form of a Beta2-adrenergic agonist quinolin-2-one derivative | ADRB2, ADRA2B, ADRB1 | HPGDS 1770/4885CNR2 79/4885CNR1 176/4885 |
| US-20070225329-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB3, ADRB1 | HPGDS 3810/4885CNR2 35/4885CNR1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.